1618-36-6

Basic information

• Product Name: 4-Chloro-5-methyl-7H-pyrrolo[2,3-d]pyrimidine
• Synonyms: 4-Chloro-5-methyl-7H-pyrrolo[2,3-d]pyrimidine;7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-5-methyl-;4-Chloro-5-Methyl-7H-pyrr...
• CAS NO: 1618-36-6
• Molecular Formula: C₇H₆ClN₃
• Molecular Weight: 167.6
• Product Categories: Heterocycle-Pyrimidine series
• Mol File: 1618-36-6.mol
• Article Data: 12

Chemical Properties

• Melting Point: 227-228 °C (decomp)
• Boiling Point: 280 °C
• Flash Point: 123 °C
• Appearance: /
• Density: 1.51
• Vapor Pressure: 0.00391mmHg at 25°C
• Refractive Index: 1.71
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 11.75±0.20(Predicted)
• CAS DataBase Reference: 4-Chloro-5-methyl-7H-pyrrolo[2,3-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloro-5-methyl-7H-pyrrolo[2,3-d]pyrimidine(1618-36-6)
• EPA Substance Registry System: 4-Chloro-5-methyl-7H-pyrrolo[2,3-d]pyrimidine(1618-36-6)

Safety Data

• Hazardous Substances Data: 1618-36-6(Hazardous Substances Data)

Usage

General Description

4-Chloro-5-methyl-7H-pyrrolo[2,3-d]pyrimidine is a chemical compound with the molecular formula C7H6N3Cl. It is a heterocyclic compound that contains both nitrogen and chlorine atoms. 4-Chloro-5-methyl-7H-pyrrolo[2,3-d]pyrimidine has potential applications in the pharmaceutical industry and as a precursor in organic synthesis. It has been studied for its potential uses in medicinal chemistry and drug discovery, with research focusing on its biological activity and potential therapeutic applications. The compound's unique structure and properties make it a promising candidate for future research and development in the field of organic chemistry and drug design.

InChI:InChI=1/C7H6ClN3/c1-4-2-9-7-5(4)6(8)10-3-11-7/h2-3H,1H3,(H,9,10,11)

Upstream product

• 1020110-72-8 2-amino-4-methyl-1H-pyrrole-3-carboxamide 
• 1618-37-7 5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ol 
• 22276-95-5 5-bromo-4-chloro-7H-pyrrolo[2,3-d]pyrimidine 
• 74-88-4 methyl iodide 
• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 

Downstream Products

• 1613479-21-2 C₁₃H₉F₂N₃O 
• 1219727-83-9 3-[2-fluoro-4-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]-1-(2-hydroxyethyl)-1-phenylurea 
• 1351089-89-8 N-methyl-3-[(5-methyl-1H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]benzenesulfonamide 
• 1351092-13-1 N-methyl-3-[(5-methyl-1H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-4-(4-morpholinyl)benzenesulfonamide 

Relevant articles and documents

4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER

The present invention concerns a compound of formula (I), in particular as LIMK and/or ROCK kinases inhibitors. The present invention also concerns these new inhibitors for use for the treatment of a condition selected in the group consisting of: cancers, virion infections, ocular hypertension and glaucoma formation, Neurofibromatosis type 1 and 2, psoriatic lesions, inflammatory diseases and hyperalgesia, central sensitization and chronic pain, reproduction erectile dysfunction, and neuronal diseases. The present description discloses the syntheses and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 32 to 127; examples 1 to 96; families 1 to 8; compounds; biological studies; tables). An exemplary compound is e.g. 4-(5-m ethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-phenyl-3,6-dihydropyridine-1-(2H)-carboxamide (example 1; compound 5).

ASK1 INHIBITING PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES

The present invention relates to pyrrolopyrimidine compounds according to Formula (I) and their use in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases. In a particular aspect, the present compounds are ASK inhibitors, particularly ASK1 inhibitors. The present invention also provides methods for the production of a compound of the invention, pharmaceutical compositions comprising a compound of the invention, the use of the compounds in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases. (Formula (I))

Discovery of a 4-aryloxy-1H-pyrrolo[3,2-c]pyridine and a 1-aryloxyisoquinoline series of TRPA1 antagonists

A series of TRPA1 antagonists is described having a 4-aryloxy-1H-pyrrolo[3,2-c]pyridine or a 1-aryloxyisoquinoline scaffold. These compounds have high ligand efficiency and favorable physical properties and may thus serve as scaffolds for further optimization.